Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 42
Filtrar
2.
J Neural Transm (Vienna) ; 111(5): 631-40, 2004 May.
Artículo en Inglés | MEDLINE | ID: mdl-15088156

RESUMEN

Cerebrospinal fluid levels of methionine (MET), homocysteine (HCY) and cystathionine were studied in patients with psychotic disorders (n=36) and in healthy controls (n=25). Patients had significantly higher MET than controls (p<0.00001), and ten of the patients had MET levels above anyone of the controls. Moreover, three young male patients had HCY levels highly above any of the controls. There were no significant gender differences in any of the parameters. Neither ageing nor neuroleptic treatment offered an explanation for the increase of MET, because also young and drug-naive patients had significantly higher MET than the controls. We conclude that patients with psychotic disorders, at least in a phase of acute exacerbation, are often in a state of disturbed one-carbon metabolism.


Asunto(s)
Metionina/líquido cefalorraquídeo , Trastornos Psicóticos/líquido cefalorraquídeo , Adulto , Biomarcadores/líquido cefalorraquídeo , Cistationina/líquido cefalorraquídeo , Femenino , Homocisteína/líquido cefalorraquídeo , Humanos , Masculino , Persona de Mediana Edad , Factores Sexuales
3.
Eur J Clin Microbiol Infect Dis ; 23(2): 98-105, 2004 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-14735403

RESUMEN

The aims of this study were to evaluate the serological response to treatment with staphylococcal vaccine in fibromyalgia/chronic fatigue syndrome patients and to explore the relationship between serological response and clinical effect. Twenty-eight patients, half of whom served as controls, were recruited from a 6-month randomised trial in which repeated administration of the staphylococcal toxoid vaccine Staphypan Berna (Berna Biotech, Switzerland) was tested against placebo. Antibody status against extracellular toxins/enzymes, cell-wall components, and enterotoxins was evaluated at baseline and at endpoint. The clinical response to treatment was recorded in rating scales. In the group receiving active treatment, significant serological changes were recorded, whereas no significant changes were found in controls. Treatment led to a significantly increased capacity of serum to neutralise alpha-toxin and a significant increase in serum IgG to alpha-toxin and lipase. Furthermore, the increase in these parameters combined paralleled the improvement in clinical outcome. Thus, the greater the serological response, the greater was the clinical effect. In conclusion, this explorative study has shown that repeated administration of the Staphypan Berna vaccine in patients with fibromyalgia/chronic fatigue syndrome causes a serological response to several staphylococcal antigens, particularly to certain extracellular toxins and enzymes. The results further show that this response is related to the clinical outcome of treatment.


Asunto(s)
Anticuerpos Antibacterianos/análisis , Síndrome de Fatiga Crónica/inmunología , Síndrome de Fatiga Crónica/terapia , Fibromialgia/inmunología , Fibromialgia/terapia , Vacunas Estafilocócicas/uso terapéutico , Adulto , Ensayo de Inmunoadsorción Enzimática , Síndrome de Fatiga Crónica/complicaciones , Femenino , Fibromialgia/complicaciones , Estudios de Seguimiento , Humanos , Inmunidad/fisiología , Masculino , Persona de Mediana Edad , Probabilidad , Valores de Referencia , Medición de Riesgo , Pruebas Serológicas , Estadísticas no Paramétricas , Resultado del Tratamiento
4.
Hum Reprod ; 17(12): 3033-6, 2002 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-12456598

RESUMEN

BACKGROUND: The remethylation cycle of methionine is folate and vitamin B(12) (cobalamin) dependent and appears to be crucial for embryonic development, probably through effects on synthesis of DNA, proteins and polyamines. Transcobalamin (TC) transports vitamin B(12) to the tissues. The objective of the present investigation was to explore the putative association between the major TC genetic polymorphism (Pro259Arg) and human spontaneous abortion. METHODS: The prevalence of the TC Pro259Arg polymorphism was determined in DNA samples from embryos that had been spontaneously aborted between the 6th and 20th week after conception, and adult controls using solid-phase minisequencing technique. RESULTS: The 259-Pro allele was significantly less frequent in the spontaneous abortion group than in the control group (42.2 and 57.0% respectively; P = 0.005), while the frequency of 259-Arg was significantly increased. There was a lower prevalence of 259-Pro homozygotes in the spontaneous abortion group compared with the control group (9.1 and 32.2% respectively; P < 0.001). CONCLUSIONS: The 259-Pro allele seems to have beneficial influences during embryogenesis, conceivably through its positive effect on vitamin B(12) intracellular bioavailability. Our results warrant additional investigations addressing the question if vitamin B(12) supplementation in addition to folic acid supplementation may prevent spontaneous abortion in women planning a pregnancy.


Asunto(s)
Aborto Espontáneo/genética , Codón , Polimorfismo Genético , Transcobalaminas/genética , Alelos , Arginina , Femenino , Frecuencia de los Genes , Predisposición Genética a la Enfermedad , Edad Gestacional , Homocigoto , Humanos , Embarazo , Prolina
5.
Neurology ; 58(9): 1395-9, 2002 May 14.
Artículo en Inglés | MEDLINE | ID: mdl-12011287

RESUMEN

Moderately elevated total serum homocysteine is associated with an increased risk of atherothrombotic vascular events. Accordingly, serum homocysteine is increased in patients with vascular dementia but is also increased in clinically diagnosed and histologically confirmed AD. It is generally considered that homocysteine potentiates endothelial and neuronal oxidative injury in these diseases. A complementary model of oxidative stress-induced hyperhomocystinemia is proposed by the authors. The hypothesis accounts for several unusual features relating to single-carbon metabolism and AD, including the absence of macrocytic anemia in these patients. It is suggested that cerebral oxidative stress augments the oxidation of an intermediate form of vitamin B(12) (cob[I]alamin) generated in the methionine synthase reaction, thereby impairing the metabolism of homocysteine. Oxidative stress also compromises the intraneuronal reduction of the vitamin to its metabolically active state. Currently available pharmaceutic forms of vitamin B(12) are unlikely to be utilized by neurons under these conditions. Glutathionylcobalamin might be preferential for the treatment of such patients.


Asunto(s)
Enfermedad de Alzheimer/etiología , Enfermedad de Alzheimer/metabolismo , Homocisteína/metabolismo , Deficiencia de Vitamina B 12/complicaciones , Deficiencia de Vitamina B 12/metabolismo , 5-Metiltetrahidrofolato-Homocisteína S-Metiltransferasa/deficiencia , Encéfalo/metabolismo , Humanos , Hiperhomocisteinemia/etiología , Oxidación-Reducción , Estrés Oxidativo , Vitamina B 12/metabolismo
7.
Dement Geriatr Cogn Disord ; 12(6): 408-14, 2001.
Artículo en Inglés | MEDLINE | ID: mdl-11598313

RESUMEN

As heavy metal ions may be implicated in the formation of senile plaques in Alzheimer-afflicted brains, treatment with clioquinol was tested in 20 patients with Alzheimer's disease. Clioquinol is a chelator that crosses the blood-brain barrier and has greater affinity for zinc and copper ions than for calcium and magnesium ions. Treatment was given for 21 days at doses of 20 mg/day to 10 patients and 80 mg/day to another 10 patients. The study was blind to the dosages but included no controls. Cerebrospinal fluid (CSF) investigations revealed a significant increase at day 7 and a decrease at day 21 in Tau protein and growth-associated protein (GAP43). These proteins are increased in Alzheimer's disease and considered as rather stable markers. The initial increase may indicate a temporary cytotoxicity to the brain and/or an increased release into the CSF from stores in the tissue, possibly from senile plaques where the proteins are accumulated. The levels of CSF-Tau protein correlated positively and significantly with the serum levels of copper and also with the serum copper/zinc ratio. Clinical ratings showed slight improvement after 3 weeks treatment with clioquinol in this open study.


Asunto(s)
Enfermedad de Alzheimer/tratamiento farmacológico , Quelantes/uso terapéutico , Clioquinol/uso terapéutico , Proteína GAP-43/efectos de los fármacos , Proteínas tau/efectos de los fármacos , Anciano , Anciano de 80 o más Años , Enfermedad de Alzheimer/sangre , Enfermedad de Alzheimer/líquido cefalorraquídeo , Quelantes/administración & dosificación , Quelantes/efectos adversos , Terapia por Quelación/métodos , Clioquinol/administración & dosificación , Clioquinol/efectos adversos , Cobre/sangre , Relación Dosis-Respuesta a Droga , Femenino , Proteína GAP-43/líquido cefalorraquídeo , Humanos , Masculino , Persona de Mediana Edad , Resultado del Tratamiento , Zinc/sangre , Proteínas tau/líquido cefalorraquídeo
8.
J Geriatr Psychiatry Neurol ; 14(3): 109-14, 2001.
Artículo en Inglés | MEDLINE | ID: mdl-11563432

RESUMEN

In the present report, 101 ambulatory elderly patients complaining about cognitive disturbances were investigated using the Mini-Mental State Examination (MMSE). Laboratory investigations, brain imaging, and electroencephalography were performed. Twelve patients were diagnosed with subjective memory complaints (SMC), 32 with mild cognitive impairment (MCI), 43 with dementia of the Alzheimer type (DAT), and 14 with vascular dementia (VAD). Thirty-three percent of the SMC group, 31% of the MCI group, 45% of the DAT group, and 62% of the VAD group had increased serum homocysteine (s-HCY). Principal component analysis of 19 variables showed 3 significant principal components by cross-validation. The cognitive impairment in the patients (MMSE) was explained to 50%. According to the principal component analysis, the population followed two different routes to cognitive impairment: one correlated with disturbance of one-carbon metabolism (cerebrospinal fluid vitamin B12, plasma B12, plasma folate, and s-HCY) and the other correlated with more classic dementia, as marked by cerebrospinal fluid tau, vascular risk factors, atrophy on brain imaging, possession of the apolipoprotein E4 allele, and age. There was poor discrimination between DAT and VAD.


Asunto(s)
Enfermedad de Alzheimer/diagnóstico , Enfermedad de Alzheimer/metabolismo , Trastornos del Conocimiento/diagnóstico , Demencia Vascular/diagnóstico , Demencia Vascular/metabolismo , Ácido Fólico/sangre , Homocisteína/sangre , Vitamina B 12/sangre , Vitamina B 12/líquido cefalorraquídeo , Proteínas tau/líquido cefalorraquídeo , Anciano , Anciano de 80 o más Años , Enfermedad de Alzheimer/genética , Apolipoproteínas E/genética , Atrofia/patología , Encéfalo/metabolismo , Encéfalo/patología , Demencia Vascular/genética , Diagnóstico Diferencial , Femenino , Humanos , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Pruebas Neuropsicológicas , Valores de Referencia , Índice de Severidad de la Enfermedad
9.
Acta Neurol Scand ; 103(3): 166-74, 2001 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-11240564

RESUMEN

A growing body of evidence points out the potential role of inflammatory mechanisms in the pathophysiology of brain damage in dementia. The aim of the present study was to investigate patterns of local and systemic cytokine release in patients with Alzheimer's disease (AD) and vascular dementia (VAD). The intrathecal levels of cytokines were related to neuronal damage and cerebral apoptosis. Twenty patients with early AD and 26 patients with VAD were analyzed with respect to cerebrospinal fluid (CSF) and serum levels of pro- and anti-inflammatory cytokines. In addition, CSF levels of Fas/APO-1 and bcl-2, a measure for apoptosis, and Tau protein, a marker for neuronal degradation, were studied. Significantly increased CSF levels of GM-CSF but not of other cytokines were observed in both dementia groups. These patients displayed a significant correlation between the GM-CSF levels and the levels of Fas/APO-1 and Tau protein in CSF. Our study demonstrates an intrathecal production of GM-CSF, a cytokine stimulating microglial cell growth and exerting inflammatogenic properties. It is suggested that GM-CSF once secreted induces programmed cell death in the brain tissue of patients with dementia.


Asunto(s)
Enfermedad de Alzheimer/patología , Apoptosis , Encéfalo/patología , Demencia Vascular/patología , Factor Estimulante de Colonias de Granulocitos y Macrófagos/sangre , Factor Estimulante de Colonias de Granulocitos y Macrófagos/líquido cefalorraquídeo , Anciano , Femenino , Humanos , Masculino , Microglía , Persona de Mediana Edad , Neuronas/patología
10.
Dement Geriatr Cogn Disord ; 12(2): 133-7, 2001.
Artículo en Inglés | MEDLINE | ID: mdl-11173886

RESUMEN

Vitamin B12 assimilation might be disrupted in patients with Alzheimer's disease. We therefore measured B12 carrier protein saturation and inactive B12 'analogues' in patients compared with healthy elderly individuals in a prospective case-controlled survey. Twenty-three patients, aged 60 or over, with features compatible with DSM-IV criteria for primary degenerative dementia of the Alzheimer type were recruited together with 18 cognitively intact age-matched control subjects. Total vitamin B12 (active corrinoids), holo- and apo-haptocorrin and transcobalamin were measured in serum. B12 analogues (inactive corrinoids) were estimated from the difference between R-binder-determined corrinoids and an intrinsic factor based B12 assay. Alzheimer patients had significantly lower active corrinoid than control subjects and the analogue/corrinoid ratio was significantly higher in the Alzheimer group. The inter-relationship between age, analogues and transcobalamin polarised patients into two distinct groups. Two disparate mechanisms might exist for the development of cerebral B12 deficiency in Alzheimer's disease, although both imply a disruption of selective B12 assimilation and analogue elimination in such patients.


Asunto(s)
Envejecimiento/fisiología , Enfermedad de Alzheimer/sangre , Vitamina B 12/análogos & derivados , Vitamina B 12/sangre , Anciano , Estudios de Casos y Controles , Femenino , Humanos , Masculino , Estudios Prospectivos
11.
Eur Neurol ; 44(4): 229-35, 2000.
Artículo en Inglés | MEDLINE | ID: mdl-11096223

RESUMEN

The aim was to study the frequently found white-matter changes on computerized tomography (CT) in patients with dementia and to relate these changes to clinical regional brain symptomatology, vascular factors, albumin ratio [indicator of blood-brain barrier (BBB) function] and other CT changes. The study included 85 patients, average age 71 +/- 8, with Alzheimer's disease (n = 56) and vascular dementia (n = 29), who underwent CT (Siemens Somatome DR 1) of the brain. They were inpatients in a psychiatric department specialized in dementia investigations. The degree of CT white-matter changes (absence, mild-moderate, severe) was the basis for the division of the patients into three groups. As the patients without white-matter changes were significantly younger than those with such changes, all statistical analyses were controlled for age. Subcortical symptomatology was significantly more frequent in the group with severe white-matter changes, whereas the reverse was true for parietal symptomatology. Diabetes mellitus, hypertension, ischemic cardiac disease and lacunas were significantly more common in patients with white-matter changes, whereas the frequency of transient ischemic attack/stroke episodes did not differ significantly between the groups. The albumin ratio was significantly higher in the groups with white-matter changes and highest in the group with severe white-matter changes. The findings indicate that white-matter changes in demented patients are at least partially an age- and stroke-independent disease manifestation of the vascular system and is associated with a specific symptom pattern. BBB dysfunction may be the link between the vasculature and the tissue damage.


Asunto(s)
Barrera Hematoencefálica/fisiología , Arterias Cerebrales/patología , Trastornos Cerebrovasculares/complicaciones , Demencia/etiología , Demencia/patología , Fibras Nerviosas Mielínicas/patología , Telencéfalo/patología , Anciano , Albúminas/líquido cefalorraquídeo , Infarto Encefálico/etiología , Infarto Encefálico/patología , Arterias Cerebrales/fisiopatología , Trastornos Cerebrovasculares/patología , Trastornos Cerebrovasculares/fisiopatología , Demencia/fisiopatología , Progresión de la Enfermedad , Femenino , Humanos , Masculino , Factores de Riesgo , Albúmina Sérica/metabolismo , Telencéfalo/irrigación sanguínea , Telencéfalo/fisiopatología
12.
J Neural Transm (Vienna) ; 107(8-9): 1065-79, 2000.
Artículo en Inglés | MEDLINE | ID: mdl-11041282

RESUMEN

A polymorphism consisting of a deletion near the 5' splice site of exon 18 on the alpha2-macroglobulin (A2M) gene (A2M-2) has been suggested to be associated with Alzheimer's disease (AD) in family-based studies. We studied the A2M-2 allele together with the ApoE alleles in a large series on patients with AD (n = 449) and age-matched controls (n = 349). Neuropathologically confirmed diagnoses were available in 199 cases (94 AD and 107 control cases). We found no increase in A2M-2 genotype or allele frequencies in AD (27.5% and 14.6%) versus controls (26.4% and 14.9%). In contrast, a marked increase (p < 0.0001) in ApoE epsilon4 genotype or allele frequencies was found in AD (66.6% and 41.2%) as compared with controls (29.8% and 16.5%), suggesting sufficient statistical power in our sample. No relation was found between the A2M-2 and the ApoE epsilon4 allele. No change in A2M exon 17-18 mRNA size or sequence or A2M protein size was found in cases carrying the A2M-2 deletion, suggesting that there is no biological consequences of the A2M intronic deletion. No change in A2M protein level in cerebrospinal fluid was found in AD, suggesting that the A2M-2 allele does not effect the A2M protein expression in the brain. The lack of an association between the A2M-2 allele and AD in the present study, and the lack of abnormalities in the A2M mRNA or protein suggest that the A2M-2 allele is not associated with AD.


Asunto(s)
Enfermedad de Alzheimer/genética , Eliminación de Gen , alfa-Macroglobulinas/genética , Anciano , Enfermedad de Alzheimer/patología , Apolipoproteína E4 , Apolipoproteínas E/genética , Secuencia de Bases , Western Blotting , Electroforesis en Gel de Poliacrilamida , Femenino , Expresión Génica , Frecuencia de los Genes , Predisposición Genética a la Enfermedad , Genotipo , Humanos , Masculino , Datos de Secuencia Molecular , Placa Amiloide/patología , Polimorfismo Genético , ARN Mensajero/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Análisis de Secuencia de ADN , Población Blanca/genética , alfa-Macroglobulinas/análisis , alfa-Macroglobulinas/líquido cefalorraquídeo
14.
Eur Neuropsychopharmacol ; 9(4): 311-5, 1999 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-10422891

RESUMEN

The granins (secretogranins/chromogranins) are a family of soluble proteins stored and released from the secretory large dense-core vesicles of the synapse. Schizophrenia is a common and devastating brain disorder. Although the aetiology of schizophrenia is unknown, data are accumulating that synaptic disturbance or damage may be of importance. The objective of this study was to compare the levels of chromogranin A, B and C in the cerebrospinal fluid (CSF) of patients with schizophrenia and healthy controls. CSF chromogranin levels were measured by RIA in 33 subsequent admissions of patients with psychotic disorder and in 31 healthy controls. The levels of CSF chromogranin A (11.8+/-3.0 vs 14.8+/-4.8 nmol/l, P=0.004), chromogranin B (3.4+/-0.49 vs 3.7+/-0.58 nmol/l, P=0.02), but not chromogranin C (70.2+/-15.7 vs 65.3+/-20.4 pmol/l, P=0.29) were lower in the schizophrenic patients than in the healthy controls. These data indicate that two widespread constituents of large dense-core vesicles, i.e. chromogranin A and chromogranin B, are altered in chronic schizophrenic patients.


Asunto(s)
Cromograninas/líquido cefalorraquídeo , Proteínas , Esquizofrenia/líquido cefalorraquídeo , Adulto , Estudios de Casos y Controles , Cromogranina A , Femenino , Humanos , Masculino , Persona de Mediana Edad
15.
Dement Geriatr Cogn Disord ; 10(4): 245-51, 1999.
Artículo en Inglés | MEDLINE | ID: mdl-10364640

RESUMEN

The gene for apolipoprotein E (APOE) is polymorphic, and its variant APOE4 is a major risk factor for the development of Alzheimer-type dementia (AD). Another risk factor for AD appears to be negative cobalamin balance, which is very common in elderly people. Cobalamin and folate are interdependent and essential components of the one-carbon metabolism. Another important component is methylenetetrahydrofolate reductase (MTHFR), the gene for which is also polymorphic. Thermolabile MTHFR (tMTHFR), a gene variant that reduces the activity of its enzyme, is common in the general population. In the present study, 75% of 140 AD patients had at least one APOE4 allele. The numbers of APOE4 and tMTHFR alleles correlated significantly with the serum folate levels, however, in opposite directions. The significance of this was augmented by an inverse correlation between APOE4 and tMTHFR. Thus, not only MTHFR but also APOE appears to be related to the one-carbon metabolism, suggesting that APOE4 and insufficient one-carbon metabolism may be synergistic risk factors for AD.


Asunto(s)
Enfermedad de Alzheimer/genética , Apolipoproteínas E/genética , Oxidorreductasas actuantes sobre Donantes de Grupo CH-NH/genética , Anciano , Envejecimiento/fisiología , Enfermedad de Alzheimer/fisiopatología , Apolipoproteína E4 , Apolipoproteínas E/metabolismo , Daño del ADN/genética , Daño del ADN/fisiología , Femenino , Antagonistas del Ácido Fólico/metabolismo , Genotipo , Humanos , Masculino , Metilación , Metilenotetrahidrofolato Reductasa (NADPH2) , Persona de Mediana Edad , Oxidorreductasas actuantes sobre Donantes de Grupo CH-NH/metabolismo , Polimorfismo Genético , Factores Sexuales , Vitamina B 12/sangre , Vitamina B 12/metabolismo
16.
Dement Geriatr Cogn Disord ; 10(1): 12-20, 1999.
Artículo en Inglés | MEDLINE | ID: mdl-9844033

RESUMEN

In 336 consecutive patients attending a university-affiliated memory unit, clinical and psychological findings, neuroimaging and laboratory tests were analyzed. The patients were diagnosed with early Alzheimer's disease 3%, senile dementia (SDAT) 16%, vascular dementia (VAD) 20%, other dementias 9%, minor cognitive impairment (dysmentia) 32% and subjective symptoms only 21%. Increases in vascular risk factors, serum homocysteine, ApoE4 load and neuroimaging pathology were found in dementia but also in dysmentia and in patients with subjective symptoms only. The homocysteine levels correlated inversely with cognitive performance. The increases in serum homocysteine, which were pathological in VAD, Dysmentia and SDAT, may be indicative of a disturbed cerebral one-carbon metabolism and signal-accelerated development of cognitive disease.


Asunto(s)
Trastornos del Conocimiento/diagnóstico , Homocisteína/sangre , Anciano , Alelos , Apolipoproteínas E/sangre , Biomarcadores , Encéfalo/patología , Trastornos del Conocimiento/sangre , Trastornos del Conocimiento/psicología , Electroencefalografía , Femenino , Humanos , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Escalas de Valoración Psiquiátrica , Análisis de Regresión , Factores de Riesgo
17.
J Neural Transm (Vienna) ; 105(8-9): 773-86, 1998.
Artículo en Inglés | MEDLINE | ID: mdl-9869318

RESUMEN

In dementia disorders, it can be assumed that the pathological process in the brain has been present for a long time. It is therefore of importance to have a preclinical or an early clinical diagnosis. Obviously, vulnerability genes, such as ApoE-4, can be diagnosed preclinically. As we have no treatment to offer patients with genetic risk factors, genotyping for ApoE-4 is at present of no clinical use. Trained neuropsychologists have today access to sensitive tests which reveal cognitive impairment before the disturbances reach the level of dementia. Laboratory investigations of cerebrospinal fluid have so far yielded no great results. Tau protein appears to be the most sensitive marker, but it is unspecific. Chromogranin A separates early onset from late onset Alzheimer's disease and seems to be a marker for synaptic degeneration. Synaptotagmin was also found to be reduced in patients with early onset Alzheimer's disease. Still we do not know, however, whether these proteins are early markers for degenerative processes in the brain. Laboratory investigations of blood have not yielded markers of use in early or differential diagnosis of dementia disorders. In a study at our own institute, however, we found serum-homocysteine (S-HCY) to be an early and sensitive marker for cognitive impairment. In patients with dysmentia (mild cognitive impairment), no less than 39% had pathological S-HCY levels, indicating insufficient 1-carbon metabolism.


Asunto(s)
Envejecimiento/psicología , Enfermedad de Alzheimer/diagnóstico , Trastornos del Conocimiento/diagnóstico , Atrofia , Biomarcadores , Encéfalo/patología , Diagnóstico por Imagen , Humanos , Factores de Tiempo
18.
J Neural Transm (Vienna) ; 105(10-12): 1293-305, 1998.
Artículo en Inglés | MEDLINE | ID: mdl-9928898

RESUMEN

The activity of methionine adenosyltransferase (MAT) was investigated in erythrocytes and postmortem brain specimens (cortex gyrus frontalis, hippocampus and thalamus) of patients with schizophrenia treated with neuroleptics. In comparison with the control group, abnormally low values of MAT Vmax and an increased MAT affinity towards methionine (lower Km values) were found in erythrocytes. In the brain, a regionally selective decrease of MAT Km was found in cortex gyrus frontalis but the Vmax values were however, unchanged. In the regions of cortex gyrus frontalis and hippocampus, but not in thalamus, the values of Vmax and Km were inversely correlated with the duration of schizophrenia. In rats treated for 28 days with the typical neuroleptic haloperidol and the atypical clozapine, a significant increase of MAT activity was found in the corpus striatum. There is the possibility that the changes observed in MAT activity in patients with schizophrenia are attributed to the neuroleptic medication.


Asunto(s)
Antipsicóticos/uso terapéutico , Encéfalo/efectos de los fármacos , Eritrocitos/efectos de los fármacos , Metionina Adenosiltransferasa/metabolismo , Esquizofrenia/tratamiento farmacológico , Adulto , Anciano , Anciano de 80 o más Años , Envejecimiento/metabolismo , Análisis de Varianza , Animales , Encéfalo/enzimología , Eritrocitos/enzimología , Femenino , Humanos , Masculino , Metionina Adenosiltransferasa/sangre , Persona de Mediana Edad , Cambios Post Mortem , Ratas , Ratas Sprague-Dawley , Esquizofrenia/sangre , Esquizofrenia/enzimología
19.
J Neural Transm (Vienna) ; 104(8-9): 931-41, 1997.
Artículo en Inglés | MEDLINE | ID: mdl-9451725

RESUMEN

The gene for methylenetetrahydrofolate reductase (MTHFR) has shown polymorphism in the general human population. In its homozygous form, a C677T mutation occurs in more than 5% of the grown-up population and produces a thermolabile variant which reduces the overall enzyme activity to less than 30% of normal. We investigated patients with schizophrenia-like psychosis. If hyperhomocysteinemic, their DNA-genotype for thermolabile C677T mutation was determined. Seven of 11 patients, six males and one female, were homozygous for thermolabile MTHFR. One male patient was heterozygous and all three normal homozygotes were females. In the patients who were homozygous for the C677T mutation, the homocysteine concentrations did not respond to vitamin B12 but were normalized by folate supplementation. In the normal homozygotes, however, the homocysteine concentrations were reduced by vitamin B12 alone. Our results suggest that homozygosity for thermolabile MTHFR is a risk factor for schizophrenia-like psychosis. Possibly, this risk may be reduced by folate supplementation.


Asunto(s)
Oxidorreductasas actuantes sobre Donantes de Grupo CH-NH/genética , Esquizofrenia/genética , Adolescente , Adulto , Estabilidad de Enzimas , Femenino , Homocisteína/sangre , Homocigoto , Calor , Humanos , Masculino , Metilenotetrahidrofolato Reductasa (NADPH2) , Mutación , Oxidorreductasas actuantes sobre Donantes de Grupo CH-NH/química , Oxidorreductasas actuantes sobre Donantes de Grupo CH-NH/metabolismo , Factores de Riesgo , Esquizofrenia/sangre , Esquizofrenia/enzimología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA